Linksbridge SPC
@linksbridge.bsky.social
Linksbridge expands the capacity of NGOs, IGOs, and nonprofits to improve human lives.
A social-purpose consulting and advisory firm, we help changemakers multiply their impact through creative thinking.
https://linksbridge.com/
A social-purpose consulting and advisory firm, we help changemakers multiply their impact through creative thinking.
https://linksbridge.com/
While vaccine R&D plows forward, the financial and political foundations of global immunization continue to wobble.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
CEPI-backed vaccines advance Oxford University has launched the world’s first Phase 2 clinical trial of a Nipah virus vaccine, CEPI announced Monday. The university will evaluate the ChAdOx1 NipahB ca...
www.linkedin.com
December 11, 2025 at 4:32 PM
While vaccine R&D plows forward, the financial and political foundations of global immunization continue to wobble.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Brazil's vaccine leadership is gaining momentum. The country recently approved the world's first single-dose dengue vaccine, inked international supply and tech transfer deals, and is eyeing a stronger role in PAHO Revolving Funds.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
With dengue approval, Brazil expands vaccine leadership Brazilian approval last week of the world’s first single-dose dengue vaccine—the Butantan Institute’s Butantan-DV—represented a “historic achiev...
www.linkedin.com
December 4, 2025 at 7:43 PM
Brazil's vaccine leadership is gaining momentum. The country recently approved the world's first single-dose dengue vaccine, inked international supply and tech transfer deals, and is eyeing a stronger role in PAHO Revolving Funds.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
WHO prequalification of Incepta Pharmaceuticals's generic version of the Sayana Press, a 3-month injectable contraceptive that can be self-administered, potentially gives millions more people access to a discreet, convenient, affordable option: linksbridge-8615684.hs-sites-na2.com/this-weeks-r...
October 16, 2025 at 11:50 PM
WHO prequalification of Incepta Pharmaceuticals's generic version of the Sayana Press, a 3-month injectable contraceptive that can be self-administered, potentially gives millions more people access to a discreet, convenient, affordable option: linksbridge-8615684.hs-sites-na2.com/this-weeks-r...
🚨 New publication alert!
At the first Chikungunya Global Meeting in Panama City, stakeholders reviewed insights from recent outbreaks and discussed research priorities. Linksbridge's Katelyn Dinkel presented our chikungunya vaccine demand forecasting work and is an author of the meeting report:
At the first Chikungunya Global Meeting in Panama City, stakeholders reviewed insights from recent outbreaks and discussed research priorities. Linksbridge's Katelyn Dinkel presented our chikungunya vaccine demand forecasting work and is an author of the meeting report:
Stakeholder meeting report: Chikungunya virus – recent outbreaks, vaccine development and the way forward
The International Vaccine Institute and Gorgas Institute (Gorgas Memorial Institute for Health Studies) organized the first Chikungunya Global Meeting…
www.sciencedirect.com
October 3, 2025 at 9:54 PM
🚨 New publication alert!
At the first Chikungunya Global Meeting in Panama City, stakeholders reviewed insights from recent outbreaks and discussed research priorities. Linksbridge's Katelyn Dinkel presented our chikungunya vaccine demand forecasting work and is an author of the meeting report:
At the first Chikungunya Global Meeting in Panama City, stakeholders reviewed insights from recent outbreaks and discussed research priorities. Linksbridge's Katelyn Dinkel presented our chikungunya vaccine demand forecasting work and is an author of the meeting report:
Reposted by Linksbridge SPC
Reports identify weakness in global pipeline for new antibiotics, diagnostics
The WHO says the pipeline for new antibiotics faces a "dual crisis" of scarcity and lack of innovation and that low-resource settings need simpler and faster diagnostic tests.
www.cidrap.umn.edu/a...
The WHO says the pipeline for new antibiotics faces a "dual crisis" of scarcity and lack of innovation and that low-resource settings need simpler and faster diagnostic tests.
www.cidrap.umn.edu/a...
October 3, 2025 at 8:51 PM
Reports identify weakness in global pipeline for new antibiotics, diagnostics
The WHO says the pipeline for new antibiotics faces a "dual crisis" of scarcity and lack of innovation and that low-resource settings need simpler and faster diagnostic tests.
www.cidrap.umn.edu/a...
The WHO says the pipeline for new antibiotics faces a "dual crisis" of scarcity and lack of innovation and that low-resource settings need simpler and faster diagnostic tests.
www.cidrap.umn.edu/a...
This week's issue has something for everyone: news about African vaccine manufacturing, updates on lenacapavir access, a look at MNCs' retreat from U.K. investments, results from a malaria vaccine clinical trial, and more.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
Ghana ups wager on local vaccines Ghanaian President John Dramani Mahama has committed $50 million to “fast-track” the country’s vaccine production. The funds will support Ghana’s National Vaccine Ins...
www.linkedin.com
September 18, 2025 at 2:56 PM
This week's issue has something for everyone: news about African vaccine manufacturing, updates on lenacapavir access, a look at MNCs' retreat from U.K. investments, results from a malaria vaccine clinical trial, and more.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
A Phase 3 trial has shown that the Zabdeno/Mvabea Ebola vaccine regimen induced antibody responses in pregnant women and their infants.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
PEPFAR recommits to lenacapavir access After threats to dismantle PEPFAR cast doubt over an access deal for Gilead’s lenacapavir PrEP drug, the U.S.
www.linkedin.com
September 11, 2025 at 4:26 PM
A Phase 3 trial has shown that the Zabdeno/Mvabea Ebola vaccine regimen induced antibody responses in pregnant women and their infants.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
This week's issue spotlights an impact analysis from our friends at MedAccess. The numbers are impressive: the nonprofit has reached 559 million people to date with vaccines, diagnostics and other health technologies supported by its agreements. www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
Bedaquiline price cut pushes BPaLM under $300 Indian generics manufacturer Lupin has slashed the price of its tuberculosis drug bedaquiline by 30%, bringing the cost of a six-month course of the WHO-r...
www.linkedin.com
September 4, 2025 at 5:30 PM
This week's issue spotlights an impact analysis from our friends at MedAccess. The numbers are impressive: the nonprofit has reached 559 million people to date with vaccines, diagnostics and other health technologies supported by its agreements. www.linkedin.com/pulse/linksb...
In an about-face, the U.S. FDA has suspended Valneva’s chikungunya vaccine just weeks after lifting an earlier pause on use of the jab. More on this development and other pharma news important to global health in this week's issue.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
‘Danger to health’: U.S.
www.linkedin.com
August 28, 2025 at 2:58 PM
In an about-face, the U.S. FDA has suspended Valneva’s chikungunya vaccine just weeks after lifting an earlier pause on use of the jab. More on this development and other pharma news important to global health in this week's issue.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Efforts to advance next-generation oral vaccines against polio type 1 and 3 got a boost this week with new Phase 1 trial data showing that the candidates performed similarly to their monovalent Sabin-strain comparators.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
Phase 1 findings fuel nOPV trials in children Results from a first-in-human study of novel type 1 and type 3 oral poliovirus vaccines (nOPV1 and nOPV3, respectively) in adults are bolstering the case ...
www.linkedin.com
August 21, 2025 at 7:04 PM
Efforts to advance next-generation oral vaccines against polio type 1 and 3 got a boost this week with new Phase 1 trial data showing that the candidates performed similarly to their monovalent Sabin-strain comparators.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
WHO has endorsed a new lifesaving tool in the fight against malaria. Two spatial emanator products from SC Johnson notched WHO prequalification this week, ushering in a new class of intervention for malaria vector control.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
WHO PQs first spatial emanators for vector control As insecticide resistance grows and shifting mosquito behavior threatens the effectiveness of long-standing vector control tools, WHO has prequalifie...
www.linkedin.com
August 14, 2025 at 3:33 PM
WHO has endorsed a new lifesaving tool in the fight against malaria. Two spatial emanator products from SC Johnson notched WHO prequalification this week, ushering in a new class of intervention for malaria vector control.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
BARDA is culling funding for mRNA vaccine R&D—a move public health officials say will hobble the country's capacity to combat the next pandemic. More on this development and other pharma news important to global health in this week's highlights.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
BARDA abandons mRNA vaccine R&D In a move decried by public health leaders as shortsighted and baseless, the U.S.
www.linkedin.com
August 7, 2025 at 3:02 PM
BARDA is culling funding for mRNA vaccine R&D—a move public health officials say will hobble the country's capacity to combat the next pandemic. More on this development and other pharma news important to global health in this week's highlights.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Lumbar puncture—an invasive technique with significant practical limitations—is the gold standard for diagnosing meningitis. Now, a non-invasive test may be on the horizon.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
Non-invasive test detects infant meningitis An ultrasound-based test detected meningitis in neonates and infants with 94% accuracy, offering a potential non-invasive alternative to the traditional lumbar puncture diagnostic method, according to results of an international study published last week i
www.linkedin.com
July 31, 2025 at 4:45 PM
Lumbar puncture—an invasive technique with significant practical limitations—is the gold standard for diagnosing meningitis. Now, a non-invasive test may be on the horizon.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
The early days of this week's International AIDS Society Conference on HIV Science (IAS 2025) highlighted potentially epidemic-ending interventions and an urgent need for a reimagined funding landscape.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
Funding cuts loom over AIDS Society Conference Against the backdrop of a collapsed U.S.
www.linkedin.com
July 17, 2025 at 3:45 PM
The early days of this week's International AIDS Society Conference on HIV Science (IAS 2025) highlighted potentially epidemic-ending interventions and an urgent need for a reimagined funding landscape.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Efforts to boost access to lifesaving medicines made strides this week: Novartis pledged to offer its infant-friendly antimalarial at a not-for-profit basis in malaria-endemic areas and Gilead finalized a deal with the Global Fund for its HIV PrEP drug.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
First malaria drug approved for newborns Novartis’ infant-friendly version of antimalarial Coartem has scored the first approval for a malaria drug for babies weighing less than 4.5 kilograms.
www.linkedin.com
July 10, 2025 at 5:57 PM
Efforts to boost access to lifesaving medicines made strides this week: Novartis pledged to offer its infant-friendly antimalarial at a not-for-profit basis in malaria-endemic areas and Gilead finalized a deal with the Global Fund for its HIV PrEP drug.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Gavi's recent replenishment summit scored big: vaccine makers made pledges that could unlock up to $200 million in savings for Gavi-supported programs. This week's issue unpacks these commitments and other pharma news important to global health.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
Gavi nabs price pledges from GSK, Merck, SII Manufacturer commitments at Gavi’s replenishment summit last week could save Gavi-supported programs up to $200 million by 2030, according to a press relea...
www.linkedin.com
July 3, 2025 at 4:12 PM
Gavi's recent replenishment summit scored big: vaccine makers made pledges that could unlock up to $200 million in savings for Gavi-supported programs. This week's issue unpacks these commitments and other pharma news important to global health.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
With US FDA approval of a twice-yearly shot that prevents HIV, global health actors are mobilizing to secure access. This week's issue reviews Gilead's promises and stakeholders' doubts: linksbridge-8615684.hs-sites.com/this-weeks-r...
June 27, 2025 at 11:07 PM
With US FDA approval of a twice-yearly shot that prevents HIV, global health actors are mobilizing to secure access. This week's issue reviews Gilead's promises and stakeholders' doubts: linksbridge-8615684.hs-sites.com/this-weeks-r...
This week's issue covers a flurry of vaccine development news. Among the highlights: Merck moved its dengue jab to Phase 3, GSK licensed its Shigella candidate to Bharat Biotech, and Micron Biomedical launched a trial of microarray-delivered rotavirus vaccine.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
Merck’s single-dose dengue jab enters Phase 3 Merck last week launched a Phase 3 trial of V181, its live attenuated quadrivalent vaccine candidate to prevent dengue disease regardless of prior dengue ...
www.linkedin.com
June 18, 2025 at 2:24 PM
This week's issue covers a flurry of vaccine development news. Among the highlights: Merck moved its dengue jab to Phase 3, GSK licensed its Shigella candidate to Bharat Biotech, and Micron Biomedical launched a trial of microarray-delivered rotavirus vaccine.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Amid dwindling global health funding and tightening national budgets, Tanzania is making a strategic push toward pharmaceutical independence. This week's issue covers the country's plans to domestically manufacture HIV antiretrovirals and other essential medicines.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
Tanzania plans local ARV production Amid a continuing crisis in global health funding, Tanzania has unveiled plans to manufacture HIV antiretrovirals (ARVs) and other essential medicines by bringing n...
www.linkedin.com
June 12, 2025 at 4:19 PM
Amid dwindling global health funding and tightening national budgets, Tanzania is making a strategic push toward pharmaceutical independence. This week's issue covers the country's plans to domestically manufacture HIV antiretrovirals and other essential medicines.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Amid significant funding cuts, global health stakeholders must find ways to do more with less.
That's one takeaway Linksbridge's KJ Zunigha heard in Geneva during the 78th World Health Assembly: www.linksbridge.com/resources/wh...
That's one takeaway Linksbridge's KJ Zunigha heard in Geneva during the 78th World Health Assembly: www.linksbridge.com/resources/wh...
What we heard at WHA78
The Linksbridge team's on-the-ground takeaways from the 78th World Health Assembly in Geneva.
www.linksbridge.com
June 6, 2025 at 7:24 PM
Amid significant funding cuts, global health stakeholders must find ways to do more with less.
That's one takeaway Linksbridge's KJ Zunigha heard in Geneva during the 78th World Health Assembly: www.linksbridge.com/resources/wh...
That's one takeaway Linksbridge's KJ Zunigha heard in Geneva during the 78th World Health Assembly: www.linksbridge.com/resources/wh...
The search for an elusive HIV vaccine was dealt a major blow this week when the U.S. government notified the Consortia for HIV/AIDS Vaccine Development that it would pull the plug on a yearslong investment into the group's vaccine R&D efforts.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
U.S.
www.linkedin.com
June 5, 2025 at 4:38 PM
The search for an elusive HIV vaccine was dealt a major blow this week when the U.S. government notified the Consortia for HIV/AIDS Vaccine Development that it would pull the plug on a yearslong investment into the group's vaccine R&D efforts.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
In this week's issue, we explore funding for new and urgently needed gonorrhea treatments and the U.K.'s planned launch of a landmark vaccination campaign against the disease.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
GSK-licensed UTI antibiotic succeeds in Phase 3 GSK’s $66 million gamble on Spero Therapeutics’ tebipenem antibiotic appears to be paying off: the companies announced Wednesday that a Phase 3 trial ev...
www.linkedin.com
May 29, 2025 at 6:23 PM
In this week's issue, we explore funding for new and urgently needed gonorrhea treatments and the U.K.'s planned launch of a landmark vaccination campaign against the disease.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
As they laid out Covid vaccine policy, the FDA chief & the top vaccine regulator contradicted their boss's stated views on measles jabs ("safe & highly effective," they said) while blaming falling immunization rates on ... other stuff. How much have they clarified?
pharma.linksbridge.com/news/34196
pharma.linksbridge.com/news/34196
May 22, 2025 at 9:24 PM
As they laid out Covid vaccine policy, the FDA chief & the top vaccine regulator contradicted their boss's stated views on measles jabs ("safe & highly effective," they said) while blaming falling immunization rates on ... other stuff. How much have they clarified?
pharma.linksbridge.com/news/34196
pharma.linksbridge.com/news/34196
Join our partners at @taskforce.bsky.social for a walkthrough of CAS.tools -- a resource package for more effective, efficient, and equitable health campaigns.
May 22, 2025 at 6:21 PM
Join our partners at @taskforce.bsky.social for a walkthrough of CAS.tools -- a resource package for more effective, efficient, and equitable health campaigns.
While pharma companies chase GLP-1 profits, sustainable access to affordable insulin remains out of reach for children and young people in LMICs. In this week's issue, we explore a new Access to Medicine Foundation report highlighting critical gaps in diabetes care.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...
Linksbridge Pharma: this week's highlights
African firm scores sublicense for SD Bio’s diagnostic tech A newly launched Nigerian diagnostics venture has signed the first sublicensing agreement for a technology under WHO’s Health Technology Acc...
www.linkedin.com
May 15, 2025 at 3:34 PM
While pharma companies chase GLP-1 profits, sustainable access to affordable insulin remains out of reach for children and young people in LMICs. In this week's issue, we explore a new Access to Medicine Foundation report highlighting critical gaps in diabetes care.
www.linkedin.com/pulse/linksb...
www.linkedin.com/pulse/linksb...